Longshen Rongfa (300534.SZ) announced its first-half results, with net profit of 13.7074 million yuan to mother, a year-on-year decrease of 40.67%

According to the Zhitong Finance App, Longshen Rongfa (300534.SZ) released the 2026 semi-annual report. During the reporting period, the company achieved revenue of 332 million yuan, a year-on-year decrease of 30.96%. Achieved net profit of 13.7074 million yuan attributable to shareholders of listed companies, a year-on-year decrease of 40.67%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 10.5875 million yuan, a year-on-year decrease of 65.41%.

During the reporting period, in the face of the multiple challenges of deepening pharmaceutical industry policies, intensifying competition and complex macroeconomic environments, under the overall leadership of the board of directors, the company anchored the core goals of annual production and operation, steadily promoted various business arrangements, and achieved phased work results. The company continued a healthy and stable development trend as a whole.